A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- Posted on May 31, 2026
- By CNBC
- 0 Views
- 1 min read
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
